Nanovibronix IncNASDAQ:NAOVNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.8000
- TODAY'S CHANGE (%)0.0500 (6.6667%)
- Bid / Lots0.7511/ 10
- Ask / Lots0.8000/ 1
- Open / Previous Close0.7980 / 0.7500
- Day Range
- 52 Week Range
- Volume33,459
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NAOV |
|---|---|---|
| 09:36 ET | 203 | 0.8 |
| 10:01 ET | 100 | 0.7501 |
| 10:03 ET | 5462 | 0.751 |
| 10:06 ET | 300 | 0.79065 |
| 10:33 ET | 1989 | 0.7451 |
| 11:42 ET | 873 | 0.7584 |
| 11:51 ET | 800 | 0.78 |
| 12:34 ET | 1000 | 0.79 |
| 12:38 ET | 4009 | 0.8 |
| 12:39 ET | 4637 | 0.8 |
| 01:33 ET | 700 | 0.8025 |
| 01:35 ET | 2000 | 0.8 |
| 02:00 ET | 531 | 0.7501 |
| 02:26 ET | 909 | 0.75 |
| 02:29 ET | 200 | 0.7451 |
| 02:36 ET | 5027 | 0.7499 |
| 02:42 ET | 500 | 0.7676 |
| 03:20 ET | 776 | 0.79 |
| 03:56 ET | 2000 | 0.746 |
| 03:57 ET | 100 | 0.8 |
Apr 9, 2024
NanoVibronix Issues Letter to Stockholders, from 8:30AM ET on Tuesday Apr 09, 2024 by Dow Jones
8:30AM ET on Tuesday Apr 09, 2024 by Dow Jones
Mar 28, 2024
NanoVibronix Signs Agreement for Research and Development of Next Generation PainShield and UroShield, from 8:30AM ET on Thursday Mar 28, 2024 by Dow Jones
8:30AM ET on Thursday Mar 28, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Nanovibronix Inc | 2.2M | -0.4x | --- |
SINTX Technologies Inc | 2.1M | 0.0x | --- |
Tenon Medical Inc | 2.7M | -0.1x | --- |
Vycor Medical Inc | 2.7M | -6.5x | --- |
Innovative Eyewear Inc | 3.1M | -0.4x | --- |
Remedent Inc | 1.1M | -4.2x | --- |
Company Information
NanoVibronix, Inc. is a medical device company. The Company is focused on developing noninvasive biological response-activating devices utilizing its low-intensity surface acoustic wave (SAW) technology. Its primary products consist of UroShield and PainShield. UroShield is an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy and decrease pain and discomfort associated with urinary catheter use, which markets in the United States under Food and Drug Administration (FDA) policy of enforcement discretion during the COVID-19 pandemic and is undergoing clinical testing. PainShield is a patch-based therapeutic ultrasound technology to treat pain, muscle spasm and joint contractures by delivering a localized ultrasound effect to treat pain and induce soft tissue healing in a targeted area. Its PainShield family of products includes PainShield MD and PainShield Plus.
Contact Information
- Headquarters
- 525 Executive BlvdELMSFORD, NY, United States 10523
- Phone
- 914-233-3004
- Fax
- ---
Executives
- Independent Chairman of the Board
- Christopher Fashek
- Chief Executive Officer, Director
- Brian Murphy
- Chief Financial Officer
- Stephen Brown
- Chief Medical Officer, Director
- Harold Jacob
- Independent Director
- Aurora Cassirer
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.2M |
|---|---|
Revenue (TTM) | $2.3M |
Shares Outstanding | 2.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.28 |
EPS | $-2.15 |
Book Value | $1.95 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | 1.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -150.50% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
